Eli Lilly and Co. (LLY) said Tuesday that the Phase 3 BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance.
According to the company, its neutralizing antibodies Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19 by 70 percent, and met the primary endpoint of the Phase 3 BLAZE-1 trial.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.